Zepbound (tirzepatide) has outperformed Wegovy (semaglutide) in a head-to-head clinical trial, with adults taking Zepbound losing 47% more weight on average than those taking Wegovy. After about a year and half, participants who took Zepbound lost an average of 50 pounds, while those taking Wegovy lost an average of 33 pounds.
The data also showed that people taking Zepbound were more likely to reach specific weight loss targets, with 32% losing at least 25% of their body weight compared to 16% for those taking Wegovy. The trial involved 751 participants who did not have diabetes but had other health conditions such as hypertension or cardiovascular disease.
Tirzepatide and semaglutide both mimic the effects of GLP-1, a gut hormone that stimulates insulin production and slows stomach passage. Tirzepatide also stimulates another gut hormone called GIP, which may boost its effects.
The FDA has approved versions of tirzepatide and semaglutide for type 2 diabetes and obesity treatment. Eli Lilly manufactures Zepbound for weight management, while Novo Nordisk makes Wegovy.
This new clinical trial data provides valuable insights into the effectiveness of these medications and will help healthcare providers make informed decisions about treatment choices. With its unique mechanism of action as an FDA-approved dual GIP and GLP-1 receptor agonist obesity medication, Zepbound is changing how millions manage chronic disease.
Source: https://edition.cnn.com/2024/12/04/health/zepbound-wegovy-weight-loss-eli-lilly/index.html